In recent years IDL Biotech has been working on developing a rapid test to detect lung cancer, under the project name MonoTotal® Rapid. However, further development will instead focus on creating a rapid test for breast cancer. Read the article here (Swedish)
Quantification of Thymidine Kinase 1 in serum with AroCell TK 210 ELISA is now validated for use on an open automation platform for ELISA. This enhances the application and use of the assay. We have now validated AroCell TK 210 ELISA for use on an automation platform,...
In 2019, IDL Biotech submitted a so-called Pre-submission request to the US FDA (United States Food and Drug Administration) this was done to ensure the future approval of UBC® Rapid, the companys rapid diagnostic test for bladder cancer. As of now, the company is...
A new Redeye interview with Michael Brobjer, AroCell CEO, commenting interim report for the second quarter of 2020. See the interview on Redeye's website.
IDL Biotech has appointed Subyung Park as Business Development Manager Asia with a focus on the product TUBEX® TF. Read the press release here
A publication presented in Entropy shows the value of UBC® Rapid Read the press release here and here
Redeye has today released a new research note on the previous analysis of Arocell. The full report can be found on their website. Link to Redeye's new research note.
Time: 10.00 - 12.00 CEST, June 15th 2020 On June 15, Arocell AB provides a live broadcast business update with subsequent question time led by Redeye’s analyst Oscar Bergman. CEO Michael Brobjer, together with parts of the management team, will among other things...
Link
Two abstracts accepted for the American Association of Cancer Research 2020 (AACR 2020) has now been published online. The first study entitled “Evaluation of TK1 protein changes using the AroCell TK 210 ELISA in an acute myeloid leukemia (AML) xenograft model during...
